Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Swedbank AB

Swedbank AB grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 245.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 77,400 shares of the company’s stock after purchasing an additional 55,000 shares during the period. Swedbank AB owned approximately 0.25% of Medpace worth $25,715,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of MEDP. The Manufacturers Life Insurance Company lifted its stake in shares of Medpace by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,129 shares of the company’s stock valued at $8,702,000 after purchasing an additional 94 shares during the last quarter. Mackenzie Financial Corp acquired a new position in Medpace during the 2nd quarter worth about $747,000. Northwestern Mutual Wealth Management Co. lifted its stake in Medpace by 95.7% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 225 shares of the company’s stock worth $93,000 after acquiring an additional 110 shares in the last quarter. Truist Financial Corp lifted its stake in Medpace by 21.2% during the 2nd quarter. Truist Financial Corp now owns 3,700 shares of the company’s stock worth $1,524,000 after acquiring an additional 648 shares in the last quarter. Finally, Cetera Investment Advisers lifted its stake in Medpace by 2.3% during the 2nd quarter. Cetera Investment Advisers now owns 11,757 shares of the company’s stock worth $4,842,000 after acquiring an additional 263 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the topic of several research reports. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Truist Financial reduced their price target on Medpace from $415.00 to $397.00 and set a “hold” rating on the stock in a research report on Monday, October 14th. TD Cowen reduced their price target on Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Finally, Redburn Atlantic started coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price target on the stock. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $381.44.

Medpace Stock Up 2.0 %

NASDAQ:MEDP opened at $350.04 on Friday. The stock’s 50 day moving average price is $342.11 and its 200 day moving average price is $353.38. The company has a market capitalization of $10.88 billion, a PE ratio of 30.65, a P/E/G ratio of 1.77 and a beta of 1.36. Medpace Holdings, Inc. has a 52-week low of $286.76 and a 52-week high of $459.77.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.